Titanovo Logo
Back to Cell Types

B-CPAPHomo sapiens (Human)Cancer cell line

Also known as: BCPAP, BC-PAP

🤖 AI SummaryBased on 14 publications

Quick Overview

Human thyroid cancer cell line with BRAF V600E mutation, used for thyroid cancer research.

Detailed Summary

The B-CPAP cell line is a human thyroid cancer-derived cell line characterized by the presence of the BRAF V600E mutation, a common genetic alteration in papillary thyroid carcinoma. It is widely used in research to study the molecular mechanisms underlying thyroid carcinogenesis, particularly focusing on the role of BRAF mutations in tumor progression. The cell line has been utilized in studies investigating the effects of BRAF mutations on cellular behavior, including proliferation, differentiation, and response to targeted therapies. Additionally, B-CPAP has been employed in studies examining the relationship between genetic alterations and chromosomal instability, as well as in the development of in vitro models for thyroid cancer research. Its genetic profile and biological characteristics make it a valuable tool for understanding the pathogenesis of thyroid cancer and for testing novel therapeutic strategies.

Research Applications

Molecular mechanisms of thyroid carcinogenesisBRAF V600E mutation studiesThyroid cancer drug developmentChromosomal instability analysis

Key Characteristics

BRAF V600E mutationPapillary thyroid carcinoma originUsed in in vitro models for thyroid cancer research
Generated on 6/15/2025

Basic Information

Database IDCVCL_0153
SpeciesHomo sapiens (Human)
Tissue SourceThyroid gland[UBERON:UBERON_0002046]

Donor Information

Age76
Age CategoryAdult
SexFemale

Disease Information

DiseaseThyroid carcinoma
LineageThyroid
SubtypePoorly Differentiated Thyroid Cancer
OncoTree CodeTHPD

DepMap Information

Source TypeDSMZ
Source IDACH-000456_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Asp259Tyr (c.775G>T)Unspecified-PubMed=25010205
MutationSimpleTERTc.1-124C>T (c.228C>T) (C228T)UnspecifiedIn promoterfrom parent cell line Hep-G2
MutationSimpleBRAFp.Val600Glu (c.1799T>A)Unspecified-PubMed=26214590

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
13
D13S317
12
D16S539
11,12
D18S51
13,17
D19S433
13.2,15
D21S11
30
D2S1338
18
D3S1358
16,17
D5S818
10,11
D7S820
10
D8S1179
12,13
FGA
20,23
Penta D
10,11
Penta E
5,12
TH01
6,9.3
TPOX
8,11
vWA
14,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.

Run L., Wang L.-P., Nong X.-T., Li N., Huang X., Xiao Y.

Endocrine 71:418-426(2021).

DOIPubMed

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.

Fagin J.A., Schweppe R.E.

Clin. Cancer Res. 25:3141-3151(2019).

DOIPubMedPMC

Thyrospheres from B-CPAP cell line with BRAF and TERT promoter mutations have different functional and molecular features than parental cells.

Vanni R.

J. Cancer 8:1629-1639(2017).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

Ibrahimpasic T., Ghossein R.A., Fagin J.A.

J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).

DOIPubMedPMC

Thyroid cancer cell lines: an overview.";

van Staveren W.C.G., Maenhaut C.

Front. Endocrinol. 3:133.1-133.9(2012).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Centrosomal and mitotic abnormalities in cell lines derived from papillary thyroid cancer harboring specific gene alterations.

Maric I., Viaggi S., Caria P., Frau D.V., Degan P., Vanni R.

Mol. Cytogenet. 4:26.1-26.8(2011).

DOIPubMedPMC

Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.

Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.

Clin. Cancer Res. 17:7248-7264(2011).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples.

Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.

BMC Cancer 8:371.1-371.11(2008).

DOIPubMedPMC

Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

Haugen B.R.

J. Clin. Endocrinol. Metab. 93:4331-4341(2008).

DOIPubMedPMC

Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype.

Franc B., Thomas G., Libert F., Dumont J.-E., Detours V., Maenhaut C.

Cancer Res. 67:8113-8120(2007).

DOIPubMed

Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.

Sobrinho-Simoes M.

Thyroid 17:707-715(2007).

DOIPubMed

Comprehensive conventional and molecular cytogenetic characterization of B-CPAP, a human papillary thyroid carcinoma-derived cell line.

Hernandez-Rivas J.M., Fusco A., Morton C.C., Vanni R.

Cancer Genet. Cytogenet. 151:171-177(2004).

DOIPubMed

p73 tumor-suppressor activity is impaired in human thyroid cancer.";

Vigneri P.

Cancer Res. 63:5829-5837(2003).

PubMed

Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor.

Frasca F., Vigneri P., Vella V., Vigneri R., Wang J.Y.-J.

Oncogene 20:3845-3856(2001).

DOIPubMed

Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers.

Fabien N., Fusco A., Santoro M.M., Barbier Y., Dubois P.-M., Paulin C.

Cancer 73:2206-2212(1994).

DOIPubMed

Description of a cell line established from a human thyroid papillary carcinoma and synthesizing human chorionic gonadotropin hormone.

Dubois P.-M.

C. R. Acad. Sci. III, Sci. Vie 315:493-498(1992).

PubMed